The symposium, chaired by Dr. Adrian Krainer, Cold Spring Harbor Laboratories, will provide a forum to discuss advances and issues in the field of RNA splicing. For program, click on: http://www.exonhit.com/splicing2002/index.htm
"Splicing 2002" will focus on state-of-the-art concepts and mechanisms of alternative RNA splicing, with leading scientists providing insight on the impact of alternative splicing in the onset and progression of diseases. Since the completion of the human genome sequencing, alternative RNA splicing has gained recognition as a key process in gene expression. It is also now viewed as a major event controlling gene regulation, and protein functionality and diversity.
The luncheon speaker at Splicing 2002 will be UMBI President Dr. Jennie Hunter-Cevera, an innovative leader in biotechnology with extensive background both in academia and industry. The University of Maryland Biotechnology is a research branch of the University System of Maryland, designed to advance research, training and economic development in the biotechnology sector.
"As a pioneer in the analysis of alternative splicing and its applications to discover new drugs and diagnostics, ExonHit Therapeutics felt the need for an annual scientific event in this emerging field of genomics," commented Bruno Tocqu, CEO of the company. "We are very pleased that such high profile international researchers in alternative splicing will present at this event. We hope to provide every participant with a state-of-the-art overview of alternative splicing and its i
Contact: Steve Berberich
University of Maryland Biotechnology Institute